An NRG Oncology SPPORT trial analysis found that Luminal B prostate tumors identified by the PAM50 genomic classifier predicted a much larger benefit from adding short-term hormone therapy to salvage ...

Patients with intermediate-risk prostate cancer who can safely forgo androgen deprivation therapy (ADT) may be spared its quality-of-life effects.

The companies will collaborate with AstraZeneca to advance local lab testing for a prostate cancer genomic instability ...

A comprehensive review shows circulating tumour DNA offers powerful prognostic insight across all major mCRPC treatments, but ...

AI-based research identifies ZNF268 as a potential marker of prostate cancer progression, raising hopes for more accurate ...

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer / A. Keith Stewart., Alan H. Bryce, Alan L.

It’s easy to assume having a mom or grandmother with breast cancer doesn’t impact your own health, but that’s not the case.

A study of 52,236 patients with cancer found that episodes of unintended weight loss affected 46.63% of patients and were tied to shorter overall survival.

Prosigna is available as a laboratory-developed test through Veracyte’s CLIA-certified laboratory in San Diego. The Veracyte Access Program offers financial assistance or tailored payment plans for ...

The FDA is expected to approve a new kind of blood test that may allow earlier diagnosis and less invasive, more effective ...

Men can develop breast cancer too. Learn 6 warning signs, key risk factors and when to see a doctor for unusual chest or ...

At What Stage of Cancer Is Chemotherapy Used? A Stage-by-Stage Guide / adjuvant chemotherapy, Breast Cancer Chemotherapy, ...